• Loading stock data…

Elpiscience Announces First Patient Dosed in US Phase I Clinical Trial of Anti-CD39 Monoclonal Antibody ES002 for Treatment of Advanced Solid Tumors

[#item_full_content]

Print Friendly, PDF & Email
Spread the word